{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:12:24Z","timestamp":1770822744546,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bulcan.2026.01.002","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:18:26Z","timestamp":1769775506000},"page":"224-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommandations pour la pratique clinique Nice\/Saint-Paul-de-Vence 2024\u20132025\u00a0: prise en charge du cancer du col de l\u2019ut\u00e9rus avanc\u00e9"],"prefix":"10.1016","volume":"113","author":[{"given":"Renaud","family":"Sabatier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Martin-Babau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Follana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Kalbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Deiana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coraline","family":"Dubot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Narducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-S\u00e9bastien","family":"Fr\u00e9nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1459-268X","authenticated-orcid":false,"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.01.002_bib0180","first-page":"188","article-title":"Main cancers incidence in metropolitan France in 2023 and trends since 1990","volume":"12\u201313","author":"Lap\u00f4tre-Ledoux","year":"2023","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.bulcan.2026.01.002_bib0185","series-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018","author":"Defossez","year":"2019"},{"key":"10.1016\/j.bulcan.2026.01.002_bib0190","unstructured":"SEER. 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/cervix.html."},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.002_bib0195","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1056\/NEJMra2404457","article-title":"Cervical cancer","volume":"392","author":"Tewari","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2026.01.002_bib0200","doi-asserted-by":"crossref","first-page":"6S44","DOI":"10.1016\/S0007-4551(23)00333-8","article-title":"Recommandations pour la pratique clinique Nice\/Saint-Paul-de-Vence 2022\u20132023\u00a0: prise en charge du cancer du col de l\u2019ut\u00e9rus avanc\u00e9","volume":"110","author":"Pautier","year":"2023","journal-title":"Bull Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.bulcan.2026.01.002_bib0205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ijgo.13865","article-title":"Cancer of the cervix uteri: 2021 update","volume":"155","author":"Bhatla","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.002_bib0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1148\/radiol.2019190088","article-title":"2018 FIGO staging system for uterine cervical cancer: enter cross-sectional imaging","volume":"292","author":"Lee","year":"2019","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.bulcan.2026.01.002_bib0215","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/cancers16040775","article-title":"The role of imaging in cervical cancer staging: ESGO\/ESTRO\/ESP Guidelines (Update 2023)","volume":"16","author":"Fischerova","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bulcan.2026.01.002_bib0220","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1007\/s00330-020-06909-3","article-title":"Diagnostic performance of conventional and advanced imaging modalities for assessing newly diagnosed cervical cancer: systematic review and meta-analysis","volume":"30","author":"Woo","year":"2020","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.01.002_bib0225","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ygyno.2016.05.002","article-title":"Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: results of ACRIN6671\/GOG0233 trial","volume":"142","author":"Atri","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2026.01.002_bib0230","doi-asserted-by":"crossref","DOI":"10.1177\/1533034617742311","article-title":"A network meta-analysis on the diagnostic value of different imaging methods for lymph node metastases in patients with cervical cancer","volume":"17","author":"Luo","year":"2018","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.bulcan.2026.01.002_bib0235","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00330-019-06461-9","article-title":"Diagnostic performance of MR imaging in evaluating prognostic factors in patients with cervical cancer: a meta-analysis","volume":"30","author":"Xiao","year":"2020","journal-title":"Eur Radiol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.01.002_bib0240","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1148\/rg.2020200013","article-title":"2018 FIGO staging classification for cervical cancer: added benefits of imaging","volume":"40","author":"Salib","year":"2020","journal-title":"Radiographics"},{"issue":"10","key":"10.1016\/j.bulcan.2026.01.002_bib0245","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1007\/s00330-020-07632-9","article-title":"Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018","volume":"31","author":"Manganaro","year":"2021","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.01.002_bib0250","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"21","key":"10.1016\/j.bulcan.2026.01.002_bib0255","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Long","year":"2005","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.bulcan.2026.01.002_bib0260","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.01.002_bib0265","first-page":"CD006469","article-title":"Chemotherapy for metastatic and recurrent cervical cancer","volume":"10","author":"Scatchard","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.bulcan.2026.01.002_bib0270","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III Trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.01.002_bib0275","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bulcan.2026.01.002_bib0280","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.bulcan.2026.01.002_bib0285","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"10421","key":"10.1016\/j.bulcan.2026.01.002_bib0290","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2026.01.002_bib0295","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2026.01.002_bib0315","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.1997.15.2.625","article-title":"Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix","volume":"15","author":"Verschraegen","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.01.002_bib0320","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1006\/gyno.2000.5807","article-title":"Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"77","author":"Bookman","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.01.002_bib0325","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/gyno.2000.6024","article-title":"A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"81","author":"Muderspach","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.002_bib0330","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygyno.2004.09.027","article-title":"Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"96","author":"Schilder","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.01.002_bib0335","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2005.11.048","article-title":"Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"102","author":"Rose","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.01.002_bib0340","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/COC.0b013e31803377c8","article-title":"Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study","volume":"30","author":"Garcia","year":"2007","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.002_bib0345","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/annonc\/mdp266","article-title":"Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group","volume":"21","author":"Lorusso","year":"2010","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.01.002_bib0175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2012.09.008","article-title":"Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study","volume":"127","author":"Alberts","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.002_bib0300","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.002_bib0310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.01.002_bib346","doi-asserted-by":"crossref","DOI":"10.1016\/j.bulcan.2025.11.011","article-title":"Tisotumab Vedotin \u2013 Cancer du col de l\u2019ut\u00e9rus m\u00e9tastatique ou r\u00e9cidivant en deuxi\u00e8me ligne","volume":"113","author":"Bletsas","year":"2026","journal-title":"Bull Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2026.01.002_bib0305","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126000226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126000226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:29:24Z","timestamp":1770820164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126000226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0007455126000226"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.002","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations pour la pratique clinique Nice\/Saint-Paul-de-Vence 2024\u20132025\u00a0: prise en charge du cancer du col de l\u2019ut\u00e9rus avanc\u00e9","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}